Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

HTG Molecular Diagnostics and PROOF Centre Partner to Commercialize COPD Prognostic Test

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
The license agreement provides HTG Molecular Diagnostics exclusive rights to commercialize PROOF Centre-developed gene expression blood tests for the prognosis of COPD patients who will experience frequent exacerbations.

HTG Molecular Diagnostics will develop the assay on its proprietary qNPA platform. The PROOF Centre -- a not-for-profit organization focused on developing blood tests for chronic organ disease -- will be involved in the clinical validation in Canada, and provide key opinion leader support for regulatory approval in North America.

Lung attacks are the leading cause of emergency room visits and hospitalizations among chronic disease sufferers, accounting for over $5.7 billion direct, and $6.7 billion indirect healthcare costs every year in Canada alone. According to the World Health Organization (WHO), an estimated 210 million people worldwide have COPD and three million deaths are attributed to the disease annually. WHO predicts COPD will become the third leading cause of death by 2030. A large portion of COPD-related mortality is due to lung attacks.

"The development of these blood tests has been driven by a huge unmet clinical and social need," says Dr. Bruce McManus, Director of the PROOF Centre. "This agreement with HTG Molecular Diagnostics will facilitate bringing these tests to market faster, providing physicians with tools to improve patient care and management and help alleviate suffering of patients with COPD."

Currently, physicians have limited capabilities to predict which COPD patients will suffer frequent lung attacks, episodes that result in hospitalization and a reduced quality of life. The ability to identify these patients earlier will enable physicians to intervene sooner and better tailor treatment for the individual patient to prevent future lung attacks.

TJ Johnson, CEO of HTG Molecular Diagnostics, states, "Delivery of an accurate, early predictor of frequent patient lung attacks, and providing the ability to personalize preventive care is of paramount importance to pulmonology practitioners and patients. This agreement is the first of many that HTG Molecular Diagnostics and PROOF Centre hope to have to bring medically valuable biomarker tests to the clinic."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!